Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00559962 · ClinicalTrials.gov registry record · Phase 2

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

A Phase 2 study of Hyperlipidemia, sponsored by Aegerion Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
260
Enrollment target
15
Study locations

NCT00559962 is a Phase 2 study of Hyperlipidemia that has completed, run by Aegerion Pharmaceuticals. The registered enrollment target is 260 participants, below the 400-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (35% lower). The trial reports 15 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00559962, a Phase 2 study of Hyperlipidemia, has completed, sponsored by Aegerion Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
260 participants
Enrollment target
15
Study locations

Study Summary

To determine safety and effectiveness of low-dose therapeutic AEGR-733 +/- atorvastatin, ezetimibe or fenofibrate (compared to placebo) on liver fat accumulation measured by Magnetic Resonance Spectroscopy

Conditions Studied

Hyperlipidemia

Interventions

  • DRUG placebo
  • DRUG AEGR-733

Study Locations (15)

Texas

  • Baylor College of Medicine - Houston
  • Clinical Trial Network - Houston
  • dgd Research - San Antonio

California

  • Scripps Clinic - San Diego
  • Radiant Research - Santa Rosa

Maryland

  • Health Trends Research - Baltimore
  • Johns Hopkins - Baltimore

District of Columbia

  • MedStar Research Institute - Washington D.C.

Illinois

  • Radiant Research - Chicago

Iowa

  • University of Iowa - Iowa City

Kentucky

  • LMARC - Louisville

Maine

  • Maine Research Associates - Auburn

Trial Details

FieldValue
Enrollment Target 260 participants
Start Date 2007-10
Est. Completion 2008-11
Phase Phase 2

Sponsor

Aegerion Pharmaceuticals

11 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00559962

The ClinicalTrials.gov registry entry for NCT00559962 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 400-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (35% lower). The listed sponsor is Aegerion Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hyperlipidemia appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00559962 reports 15 study locations spanning 11 distinct geographic areas - top geographies include Texas, California, Maryland.

Frequently Asked Questions

What is clinical trial NCT00559962 about?

NCT00559962 is a clinical study titled "Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS". To determine safety and effectiveness of low-dose therapeutic AEGR-733 +/- atorvastatin, ezetimibe or fenofibrate (compared to placebo) on liver fat accumulation measured by Magnetic Resonance Spectroscopy

What is the current status of trial NCT00559962?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2007-10. Estimated completion is 2008-11.

What conditions does trial NCT00559962 study?

This clinical trial studies the following conditions: Hyperlipidemia.

What interventions are being tested in trial NCT00559962?

The interventions under investigation include: placebo (DRUG), AEGR-733 (DRUG).

Who is sponsoring clinical trial NCT00559962?

This trial is sponsored by Aegerion Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00559962 being conducted?

This trial has 15 study locations across California, District of Columbia, Illinois, Iowa, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hyperlipidemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hyperlipidemia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.